Lessons prom the PROVE-IT trial - Higher dose of potent statin better for high-risk patients

Authors
Category Primary study
JournalCLEVELAND CLINIC JOURNAL OF MEDICINE
Year 2004
The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.
Epistemonikos ID: 7c9276fdd1f8ef39ff15cc1f13585a203b317b9c
First added on: Sep 30, 2023